000147646 001__ 147646
000147646 005__ 20240229112654.0
000147646 0247_ $$2doi$$a10.1093/ageing/afz127
000147646 0247_ $$2pmid$$apmid:31732737
000147646 0247_ $$2ISSN$$a0002-0729
000147646 0247_ $$2ISSN$$a1468-2834
000147646 0247_ $$2altmetric$$aaltmetric:70498600
000147646 037__ $$aDKFZ-2019-02637
000147646 041__ $$aeng
000147646 082__ $$a610
000147646 1001_ $$0P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aLaetsch, Dana Clarissa$$b0$$eFirst author
000147646 245__ $$aInvestigation of a possible association of potentially inappropriate medication for older adults and frailty in a prospective cohort study from Germany.
000147646 260__ $$aOxford$$bOxford Univ. Press$$c2019
000147646 3367_ $$2DRIVER$$aarticle
000147646 3367_ $$2DataCite$$aOutput Types/Journal article
000147646 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1636554935_12226
000147646 3367_ $$2BibTeX$$aARTICLE
000147646 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147646 3367_ $$00$$2EndNote$$aJournal Article
000147646 500__ $$a2019 Dec 1;49(1):20-25
000147646 520__ $$apotentially inappropriate medications (PIMs) are commonly defined as drugs that should be avoided in older adults because they are considered to have a negative risk-benefit ratio. PIMs are suspected to increase the risk for frailty, but this has yet to be examined.prospective population-based cohort study.a German cohort of community-dwelling older adults (≥60 years) was followed from October 2008 to September 2016.in propensity score-adjusted logistic and Cox regression models, associations between baseline PIM use and prevalent/incident frailty were investigated. Frailty was assessed using the definition by Fried and co-workers, PIM were defined with the 2015 BEERS criteria, the BEERS criteria to avoid in cognitively impaired patients (BEERS dementia PIM), the EU(7)-PIM and the PRISCUS list.of 2,865 participants, 261 were frail at baseline and 423 became frail during follow-up. Only BEERS dementia PIM use was statistically significantly associated with prevalent frailty (odds ratio (95% confidence interval), 1.51 (1.04-2.17)). The strength of the association was comparable for all frailty components. Similarly, in longitudinal analyses, only BEERS dementia PIM use was associated with incident frailty albeit not statistically significant (hazard ratio, 1.19 (0.84-1.68)).the association of PIM use and frailty seems to be restricted to drug classes, which can induce frailty symptoms (anticholinergics, benzodiazepines, z-substances and antipsychotics). Physicians are advised to perform frailty assessments before and after prescribing these drug classes to older patients and to reconsider treatment decisions in case of negative performance changes.
000147646 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000147646 588__ $$aDataset connected to CrossRef, PubMed,
000147646 7001_ $$0P:(DE-He78)747b703d2a306c4276ea9e4ee9b5fe44$$aHoppe, Liesa Katharina$$b1
000147646 7001_ $$0P:(DE-He78)97343bbd9545a4b87574e74329dabfd1$$aSaum, Kai-Uwe$$b2
000147646 7001_ $$aHaefeli, Walter E$$b3
000147646 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4
000147646 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b5$$eLast author
000147646 773__ $$0PERI:(DE-600)2065766-3$$a10.1093/ageing/afz127$$gp. afz127$$n1$$p20-25$$tAge & ageing$$v49$$x1468-2834$$y2019
000147646 909CO $$ooai:inrepo02.dkfz.de:147646$$pVDB
000147646 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000147646 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000147646 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000147646 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000147646 9141_ $$y2019
000147646 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000147646 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAGE AGEING : 2017
000147646 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147646 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147646 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000147646 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000147646 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000147646 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147646 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000147646 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147646 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147646 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147646 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000147646 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000147646 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000147646 980__ $$ajournal
000147646 980__ $$aVDB
000147646 980__ $$aI:(DE-He78)C070-20160331
000147646 980__ $$aUNRESTRICTED